CVS Caremark Corp., the nation’s largest prescription drug provider, announced plans for its largest acquisition in five years, the buyout of Coram LLC for about $2.1 billion.
In a statement, CVS announced Wednesday plans to acquire th company currently owned by Apria Healthcare Group. The move will allow CVS to expand is operations in the antibiotic, nutrition and pain therapy business through intravenous therapy.
The deal is CVS’s largest since it acquire Longs Drug Stores for $2.8 billion in 2008 following a bidding war with CVS rival Walgreens.
According to reports, the deal also marks the third-largest drug-retail acquisition deal in the past five years.
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Uruguayan Antitrust Scrutiny Puts Major Meatpacking Deal Between Marfrig and Minerva on Hold
May 19, 2024 by
CPI
Alaska Airlines Seeks Dismissal of Consumer Lawsuit Over $1.9 Billion Hawaiian Airlines Buy
May 19, 2024 by
CPI
Idaho Attorney General Orders Split of Kootenai Health and Syringa Hospital
May 19, 2024 by
CPI
Court Rejects T-Mobile’s Appeal Bid in Antitrust Case Over Sprint Merger
May 19, 2024 by
CPI
Google Requests Judge, Not Jury, to Decide on Antitrust Case
May 19, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI